AUS
NZ
UK
CA
USA
IND
Highlights:
- Medicus Pharma Ltd.has received Minor Use in Major Species Designation (MUMS) from the FDA for its Doxorubicin-containing microneedle array (D-MNA) to treat equine squamous cell carcinoma.
- The MUMS designation allows the company an exclusive marketing period of seven years, contingent upon meeting regulatory requirements.
- The D-MNA patch uses dissolvable microneedles to deliver doxorubicin directly to the tumor in horses, offering a novel non-invasive cancer treatment.
Medicus Pharma Ltd. (TSXV:MDCX), a biotechnology company focused on veterinary treatments, has announced that its investigational new animal drug (INAD) has received Minor Use in Major Species Designation (MUMS) from the U.S. Food and Drug Administration (FDA). The designation is granted to drugs intended for conditions that affect minor animal populations but in species that have a large economic significance.
Sector Focus: Veterinary Pharmaceuticals
The veterinary pharmaceutical sector is witnessing innovative advancements aimed at addressing specific animal health challenges. Medicus Pharma's recent FDA recognition places it at the forefront of the veterinary oncology market, particularly in equine healthcare. The approval of the dissolvable Doxorubicin-containing microneedle array (D-MNA) is a pivotal development in treating squamous cell carcinoma (SCC) in horses.
D-MNA Technology and Its Mechanism
The D-MNA patch is a dissolvable transdermal treatment that features cellulose-based microneedles pre-loaded with the chemotherapy drug doxorubicin. These microneedles create temporary microchannels in the skin, which allow the doxorubicin to penetrate the tumor and target cancer cells directly. Once applied, the microneedles dissolve, releasing the drug in a controlled manner, enhancing the delivery and effectiveness of the treatment.
Market Implications and Future Outlook
The MUMS designation from the FDA offers Medicus an exclusive seven-year marketing period, contingent on meeting regulatory requirements. This exclusivity could potentially provide Medicus with a competitive edge in the equine healthcare market, particularly for treating SCC, a common and difficult-to-treat cancer in horses. As of December 2024, the company is actively advancing the clinical development of its treatment, with the possibility of a commercially viable product expected as early as 2026.
Regulatory and Strategic Position
Medicus Pharma's progress with the FDA and its receipt of the MUMS designation signifies a strategic step toward securing a market-leading position in the veterinary oncology space. The designation is comparable to the Orphan Drug status for human drugs, offering significant benefits including extended market exclusivity and potentially greater support in clinical trials. This move positions Medicus to capture a key niche market and deliver innovative, non-invasive treatments to improve equine health.
